Regenera Sciences aims to be a leader in developing stem cell-based therapies that regenerate musculoskeletal tissues and heal previously irreversible debilitating orthopedic conditions in animals, with a view to future human translation

ABOUT US

Regenera’s stem cell-based therapies are a breakthrough in regenerative medicine, taking advantage of proprietary technology and experience resulting from over 20 years of academic and industry-driven research. Regenera^® leverages a deep understanding of stem cell biology to formulate the best indicated stem cells to promote unprecedented musculoskeletal tissue regeneration.

Regenera’s stem cell-based therapies have been widely validated in real clinical cases involving tendon and ligament lesions in high-performance horses and degenerative joint disease (DJD) in pet dogs, with treatments soon available for pet felines. Regenera^® stem cell-based therapies are also showing potential to be applied to humans, not only for reverting previously debilitating musculoskeletal conditions, but also to promote difficult wound healing, peripheral nerve regeneration, amelioration of cardiovascular and auto-immune conditions, and promote hair follicle homeostasis.

Regenera will support its activities by both, continuously generating new advanced therapy medicinal products, by reinvesting in disruptive internal R&D programs while embracing open innovation, and by establishing regenerative therapy and rehabilitation clinics that will simultaneously work as education and training centers for veterinarians, and human orthopaedic specialists, interested in holistic approaches to regenerative medicine.

TEAM

PROFESSOR MIGUEL SANTOS, PHD, MBA

Founding Partner and Chief Strategy
and Innovation Ofﬁcer (CSIO)

BSc and MSc degrees in Biochemistry (1993), Old Dominion University, VA, USA;
PhD in Molecular Biology, ITQB/UNL, PT;
Mini-MBA in Global Biopharma Entrepreneurship, Rutgers University, NJ, USA; & MBA from the Institute of Business Management, ISCTE/ FE Univ. Porto;
Over 20 years’ experience in Biotech R&I; over 12 years as COO & VP Chief Innovation Ofﬁcer;
Over 15 years’ experience in the development of MSC-based ATMP.

PROFESSOR ANA COLETTE MAURICIO, PHD

Founding Partner and Chief Medical Ofﬁcer (CMO)

Full Professor at ICBAS–School of Medicine and Biomedical Sciences, University of Porto (U.Porto);
Degree on Veterinary Medicine (1995), PhD on Veterinary Sciences (1999), Faculdade de Medicina Veterinária (FMV) – Universidade de Lisboa (ULisboa); Habilitation in Veterinary Sciences (2011), ICBAS-UP;
Director of the Veterinary Sciences Doctoral Program at ICBAS-UP and of CCIVV – Equine Clinical Center of Vairão (CCEV) at ICBAS-UP;
Scientiﬁc Coordinator of Regenerative Medicine and Experimental Surgery sub-unit, Centro de Estudos de Ciência Animal (CECA) of Instituto Instituto de Ciências, Tecnologias e Agroambiente da Universidade do Porto (ICETA) and of Comparative and Translational Medicine and Biotechnology from the Associated Laboratory AL4AnimalS.

PROFESSOR RITA SANTOS, PHD

Founding Partner and Chief Scientiﬁc Ofﬁcer (CSO)

PhD in Veterinary Sciences (2020) by Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto (ICBAS-UP), Portugal;
Assistant Professor and Vice-President of the Board of Directors of Escola Universitária Vasco da Gama (EUVG), Coimbra, Portugal;
Over 10 years’ experience in research in the áreas of Regenerative Medicine and Experimental Surgery, Centro de Estudos de Ciência Animal (CECA/UPorto) and Vasco da Gama Research Center (CIVG).

DR INÊS REIS, DVM

Founding Partner and Clinical Director - Equines

PhD Student in Veterinary Sciences at Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto(ICBAS-UP, Portugal) in the ﬁeld of “Equine Regenerative Medicine”;
Certiﬁed veterinarian by Federátion Equestre internationale (FEI) and Federação Equestre Portuguesa (FEP), since 2010;
Portuguese representative of equine practitioners at Federation of European Equine Veterinary Associations (FEEVA) and Federation Ibero-Americana de Veterinários de Equinos (FIAVE), since 2021;
Working Equitation Championship organizer – North Portugal.

HENRY CHAMBERLAIN

Investor Director

Career in building businesses, venture capital, M&A, SPACs and IPOs;
Investment Manager to publicly listed and private venture capital funds in consumer, media and technology;
Investment Adviser to eight special purpose vehicles (SPVs), of which seven have achieved IPOs or exited to private equity or trade;
Director of a NASDAQ-listed SPAC;
Multiple investments in biotech and medtech businesses, of which one is publicly listed on NASDAQ;
MA in History and Politics from The University of Edinburgh; FINRA Series 7, 63, 24 (investment banking) and Series 65 (investment management); FCA authorised.

Join us in making a difference in
animal and human regenerative medicine

If you would like additional information, please contact miguel@regenerasciences.com

SCIENCE

High-performance horses are prone to joint tissue lesions, which result in 79% of lost training days and 30% of all career-ending injuries. 25% of all dogs and 13% of all cats are prone to degenerative joint disease (DJD), causing pain, limiting mobility and impairing quality of life.

Current veterinary practice relies on treatments which involve the use of non-curative drugs, with severe medium-to-long term collateral effects, and/or invasive procedures such as arthroscopic surgery.

New advanced medicinal products, using live stem cells as active ingredients, have demonstrated great potential to regenerate tissues by reprogramming themselves to become newly functional cells, and by inducing the regenerative capacity of the body through secretion of biochemical signals. However, current available therapies have still shown non-consistent results and difficult market scalability due to the fact cells are taken from the injured animal (patient), and therefore administered only after a 30-day period of cell manipulation in a lab, thus missing the clinical window of opportunity, and the type of stem cells used (usually from fat tissues) are non-specific for regenerating joint tissues, such as ligaments, tendons, cartilage and muscle.

Regenera’s product Combicel^® is produced from universal donors selected according to proven scientific criteria, thus allowing for the production of off-the-shelf medicinal products which are readily available to be administered during the proper clinical window of opportunity

Combicel^® also leverages the capacity of two different types of stem cells, judiciously selected for being able to modulate local inflammatory reactions and induce intrinsic regenerative mechanisms, and naturally regenerate joint tissues, keeping their homeostasis, thus obviating the problem of lack of stem cell specificity.

Regenera’s stem cell-based therapies for high-performance horses have proven to be able to reduce stoppage times by 60% as compared to alternative treatments and bring otherwise lost-for-competition horses back to their highest performance.

Regenera’s stem cell-based therapies for pet dogs have focused on breed and age-related degenerate joint disease (osteoarthritis). Owners have reported great improvements in the animal’s freedom of movement and clear reduction of lameness signs after physical effort.

Regenera’s stem cell-based therapies are also showing potential to be applied to humans, not only for reverting previously debilitating musculoskeletal conditions, but also to promote difﬁcult wound healing, peripheral nerve regeneration, amelioration of cardiovascular and auto-immune conditions, and follicle regeneration for preventing hair loss.